Philippe specialises in cross-border and Dutch company law, mergers and acquisitions, and financing. He advises on the establishment of national and international joint ventures, and has a special focus on transactions at the interface between company law, financing and tax law. Examples include participation schemes, and special projects: one-off projects that combine these aspects with creativity. He also focuses on public-private partnerships, investment funds and restructurings. Philippe finds creative solutions for projects involving ostensibly opposing points of departure.
He lectures and is an adviser and coach for capital-intensive start-ups.
Qualifications & Experience
- Course for supervisory board members and officers (Nyenrode Business University)
- Business Management Programme (University of Cambridge, Judge Business School)
- Grotius Academy specialisation course on Companies and Business
- Erasmus programme (University of Gothenburg)
- Notarial Law (Vrije Universiteit Amsterdam)
- Postgraduate "Eurofiscus" programme (Maastricht University)
Houthoff advised a leading Dutch logistics company in respect of its corporate and financial restructuring, including obtaining new asset based credit facilities.
Harbour BioMed, a newly established cancer therapies company based in Shanghai, today announced it has bought Harbour Antibodies BV for cash and an equity stake in Harbour Biomed in order to form a new oncology biotech.
The acquisition was financed by Harbour BioMed investors, Advantech Capital and Legend Capital, two leading China-focused investors with a particular emphasis on life sciences.
Harbour BioMed was established in 2016 with an initial financing of USD 50m from Advantech Capital, Legend Capital and the Harbour BioMed founding team. The company is headquartered with R&D operations in Shanghai, business operations in Cambridge, MA, and antibody platform innovation operations in Rotterdam, The Netherlands. The company plans to expand its presence in the Boston area by establishing a drug discovery innovation center.
Houthoff assisted Erasmus MC Holding B.V., Atlas Holding Fund IX Coöperatief U.A. and the other shareholders of Harbour Antibodies B.V.
Sale of all shares in the capital of Regenboog Participaties B.V., ultimate parent of the BMC Group to Yacht Group Nederland B.V., subsidiary of Randstad.
Houthoff advised Reggeborgh on the IPO of Koninklijke VolkerWessels on Euronext Amsterdam and advised both Reggeborgh and Koninklijke VolkerWessels on all governance-related matters. This included the preparation of the articles of association, the rules of the management board, the supervisory board and its committees, policies, the relationship agreement and the IPO decision-making. VolkerWessels is a market leading construction company operating primarily in the Netherlands, the United Kingdom, Germany and North America. Reggeborgh, which is wholly owned by the Wessels family, is still a majority shareholder. The Wessels family intends to become a long-term minority shareholder of VolkerWessels over time. VolkerWessels was listed on Euronext on 12 May 2017. Reggeborgh sold 25 million shares (31.25%), valuing the company at EUR 1.84 billion. This IPO was the largest in Europe to date in 2017 (outside of technology listings).
Representing Tele2, together with Cleary Gottlieb Steen & Hamilton LLP, on the creation of a joint venture with Kazakhtelecom that will combine Tele2 Kazakhstan with Altel, Kazakhtelecom’s mobile business and the operator of the country’s only 4G network. Tele2 Kazakhstan and Altel are, respectively, the third and the fourth largest mobile operators in Kazakhstan, and the combined business will have a market share of around 22%. Both operating entities will be owned via a joint venture holding company incorporated in the Netherlands. In the context of the transaction, Tele2 will also purchase Asianet’s existing 49% stake in Tele2 Kazakhstan for an upfront consideration and a future earn-out equivalent to an 18% economic interest in the joint venture. The closing of the transaction is subject to regulatory approvals.